Drug details

Imraldi (adalimumab-xxxx injection, for subcutaneous use)

type of

Imraldi (adalimumab injection, solution) is a tumor necrosis factor (TNF) blocker used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

The drug is often used to treat Ankylosing spondylitis , Arthritis , Psoriatic arthritis , Ulcerative colitis .

This drug may have the following side effects:

• headache, and
• rash
• injection site reactions,
• infections (e.g. upper respiratory, sinusitis),

The following drugs are related to Imraldi, either as a replacement or used together:

• Abrilada (adalimumab-afzb injection, for subcutaneous use)
• Hadlima (adalimumab-bwwd injection)
• Otezla (apremilast tablets)
• Bavencio (avelumab injection)
• Avsola (infliximab-axxq for injection)
• Azasan (azathioprine)
• Baxdela (delafloxacin injection, tablets)
• Bryhali (halobetasol propionate lotion)
• Enstilar (calcipotriene and betamethasone dipropionate foam, 0.005%/0.064%)
• Duobrii (halobetasol propionate and tazarotene lotion)
• Yutiq (fluocinolone acetonide intravitreal implant)
• Simponi Aria (golimumab for infusion)
• Simponi Injection (golimumab injection)
• Rituxan (rituximab)
• Rituxan Hycela (rituximab and hyaluronidase human injection)
• Stelara Injection (ustekinumab)